Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?

Bridge SH, Pagano S, Jones M, Foster GR, Neely D, Vuilleumier N, Bassendine MF.

Hepatol Int. 2018 Jan;12(1):17-25. doi: 10.1007/s12072-018-9842-5. Epub 2018 Feb 8.

2.

Hepatitis C virus and atherosclerosis: A legacy after virologic cure?

Bassendine MF, Nielsen SU, Bridge SH, Felmlee DJ, Sheridan DA, Packard CJ, Neely RD.

Clin Res Hepatol Gastroenterol. 2017 Feb;41(1):25-30. doi: 10.1016/j.clinre.2016.09.008. Epub 2016 Nov 11. Review.

PMID:
27840032
3.

Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection.

Sheridan DA, Hajarizadeh B, Fenwick FI, Matthews GV, Applegate T, Douglas M, Neely D, Askew B, Dore GJ, Lloyd AR, George J, Bassendine MF, Grebely J.

Liver Int. 2016 Dec;36(12):1774-1782. doi: 10.1111/liv.13176. Epub 2016 Jul 5.

PMID:
27224844
4.

PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism.

Bridge SH, Sheridan DA, Felmlee DJ, Crossey MM, Fenwick FI, Lanyon CV, Dubuc G, Seidah NG, Davignon J, Thomas HC, Taylor-Robinson SD, Toms GL, Neely RD, Bassendine MF.

J Hepatol. 2015 Apr;62(4):763-70. doi: 10.1016/j.jhep.2014.11.016. Epub 2014 Nov 21.

PMID:
25463543
5.

Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency.

Sheridan DA, Bridge SH, Crossey MM, Felmlee DJ, Thomas HC, Neely RD, Taylor-Robinson SD, Bassendine MF.

Metab Brain Dis. 2014 Sep;29(3):625-34. doi: 10.1007/s11011-014-9520-9. Epub 2014 Mar 12.

PMID:
24615429
6.

Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial.

Sheridan DA, Bridge SH, Crossey MM, Felmlee DJ, Fenwick FI, Thomas HC, Neely RD, Taylor-Robinson SD, Bassendine MF.

Liver Int. 2014 May;34(5):737-47. doi: 10.1111/liv.12316. Epub 2013 Oct 14.

PMID:
24118830
7.

Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England.

McPherson S, Valappil M, Moses SE, Eltringham G, Miller C, Baxter K, Chan A, Shafiq K, Saeed A, Qureshi R, Hudson M, Bassendine MF.

J Viral Hepat. 2013 Sep;20(9):638-44. doi: 10.1111/jvh.12084. Epub 2013 Mar 12.

PMID:
23910648
8.

Lipids and HCV.

Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RD.

Semin Immunopathol. 2013 Jan;35(1):87-100. doi: 10.1007/s00281-012-0356-2. Epub 2012 Oct 31. Review.

PMID:
23111699
9.

Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).

Sheridan DA, Neely RD, Bassendine MF.

Clin Res Hepatol Gastroenterol. 2013 Feb;37(1):10-6. doi: 10.1016/j.clinre.2012.07.002. Epub 2012 Sep 5. Review.

PMID:
22959093
10.

Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity.

Sheridan DA, Bridge SH, Felmlee DJ, Crossey MM, Thomas HC, Taylor-Robinson SD, Toms GL, Neely RD, Bassendine MF.

J Hepatol. 2012 Jul;57(1):32-8. doi: 10.1016/j.jhep.2012.02.017. Epub 2012 Mar 10.

PMID:
22414761
11.

HCV and the hepatic lipid pathway as a potential treatment target.

Bassendine MF, Sheridan DA, Felmlee DJ, Bridge SH, Toms GL, Neely RD.

J Hepatol. 2011 Dec;55(6):1428-40. doi: 10.1016/j.jhep.2011.06.004. Epub 2011 Jun 28. Review.

12.

Mucocele of the cystic duct remnant after orthotopic liver transplant: a problem revisited.

Chatterjee S, Das D, Hudson M, Bassendine MF, Scott J, Oppong KE, Sen G, French JJ.

Exp Clin Transplant. 2011 Jun;9(3):214-6.

13.

Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus.

van der Laan LJ, Hudson M, McPherson S, Zondervan PE, Thomas RC, Kwekkeboom J, Lindsay AS, Burt AD, Kazemier G, Tilanus HW, Bassendine MF, Metselaar HJ.

Transplant Proc. 2010 Dec;42(10):4573-7. doi: 10.1016/j.transproceed.2010.10.013.

PMID:
21168740
14.

Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection.

Bridge SH, Sheridan DA, Felmlee DJ, Nielsen SU, Thomas HC, Taylor-Robinson SD, Neely RD, Toms GL, Bassendine MF.

Gut. 2011 May;60(5):680-7. doi: 10.1136/gut.2010.222133. Epub 2010 Oct 12.

PMID:
20940286
15.

Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles.

Felmlee DJ, Sheridan DA, Bridge SH, Nielsen SU, Milne RW, Packard CJ, Caslake MJ, McLauchlan J, Toms GL, Neely RD, Bassendine MF.

Gastroenterology. 2010 Nov;139(5):1774-83, 1783.e1-6. doi: 10.1053/j.gastro.2010.07.047. Epub 2010 Aug 2.

PMID:
20682323
16.

Antisense technology to lower LDL cholesterol.

Neely RD, Bassendine MF.

Lancet. 2010 Mar 20;375(9719):959-61. doi: 10.1016/S0140-6736(10)60364-9. No abstract available.

PMID:
20227757
17.

Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin.

Sheridan DA, Price DA, Schmid ML, Toms GL, Donaldson P, Neely D, Bassendine MF.

Aliment Pharmacol Ther. 2009 Jun 15;29(12):1282-90. doi: 10.1111/j.1365-2036.2009.04012.x. Epub 2009 Apr 8.

18.

Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.

Walker LJ, Newton J, Jones DE, Bassendine MF.

Hepatology. 2009 Jan;49(1):337-8; author reply 338. doi: 10.1002/hep.22670. No abstract available.

PMID:
19035342
19.

Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.

Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA.

J Virol. 2008 Dec;82(24):12020-9. doi: 10.1128/JVI.01569-08. Epub 2008 Oct 1.

20.

Characterization of hepatitis C RNA-containing particles from human liver by density and size.

Nielsen SU, Bassendine MF, Martin C, Lowther D, Purcell PJ, King BJ, Neely D, Toms GL.

J Gen Virol. 2008 Oct;89(Pt 10):2507-17. doi: 10.1099/vir.0.2008/000083-0.

21.

Binding of liver derived, low density hepatitis C virus to human hepatoma cells.

Martin C, Nielsen SU, Ibrahim S, Bassendine MF, Toms GL.

J Med Virol. 2008 May;80(5):816-23. doi: 10.1002/jmv.21150.

22.

HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study.

Donaldson PT, Baragiotta A, Heneghan MA, Floreani A, Venturi C, Underhill JA, Jones DE, James OF, Bassendine MF.

Hepatology. 2006 Sep;44(3):667-74.

PMID:
16941709
23.

Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients.

Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL.

J Virol. 2006 Mar;80(5):2418-28.

24.

Immunohistochemical assessment of hepatitis C virus antigen in cholestatic hepatitis after liver transplantation.

Fenwick F, Bassendine MF, Agarwal K, Bevitt D, Pumeechockchai W, Burt AD, Toms GL.

J Clin Pathol. 2006 Feb;59(2):174-8.

25.

Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection.

Price DA, Bassendine MF, Norris SM, Golding C, Toms GL, Schmid ML, Morris CM, Burt AD, Donaldson PT.

Gut. 2006 May;55(5):715-8. Epub 2005 Nov 18.

26.

Risk factors and medical follow-up of drug users tested for hepatitis C--can the risk of transmission be reduced?

Serfaty MA, Lawrie A, Smith B, Brind AM, Watson JP, Gilvarry E, Bassendine MF.

Drug Alcohol Rev. 1997 Dec;16(4):339-47.

PMID:
16203447
27.

Chemokine receptor 5 and primary biliary cirrhosis: a two-centre genetic association study.

Baragiotta A, Floreani A, Agarwal K, Venturi C, Craggs A, Jones DE, Donaldson PT, Bassendine MF.

Liver Int. 2004 Dec;24(6):646-50.

PMID:
15566517
28.

Primary biliary cirrhosis: clinical and associated autoimmune features and natural history.

Jones DE, James OF, Bassendine MF.

Clin Liver Dis. 1998 May;2(2):265-82, viii. Review.

PMID:
15560032
29.

Primary biliary cirrhosis: report of a focus study group.

Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ.

Hepatology. 2004 Oct;40(4):1013-20. Review. No abstract available.

PMID:
15382160
30.

Tamoxifen: a novel treatment for primary biliary cirrhosis?

Reddy A, Prince M, James OF, Jain S, Bassendine MF.

Liver Int. 2004 Jun;24(3):194-7.

PMID:
15189268
31.

Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver.

Nielsen SU, Bassendine MF, Burt AD, Bevitt DJ, Toms GL.

J Gen Virol. 2004 Jun;85(Pt 6):1497-507.

32.

Hepatitis C virus particles of different density in the blood of chronically infected immunocompetent and immunodeficient patients: Implications for virus clearance by antibody.

Pumeechockchai W, Bevitt D, Agarwal K, Petropoulou T, Langer BC, Belohradsky B, Bassendine MF, Toms GL.

J Med Virol. 2002 Nov;68(3):335-42.

PMID:
12226819
33.

The true impact of fatigue in primary biliary cirrhosis: a population study.

Goldblatt J, Taylor PJ, Lipman T, Prince MI, Baragiotta A, Bassendine MF, James OF, Jones DE.

Gastroenterology. 2002 May;122(5):1235-41.

PMID:
11984509
34.

Hepatitis associated with Chinese herbs.

McRae CA, Agarwal K, Mutimer D, Bassendine MF.

Eur J Gastroenterol Hepatol. 2002 May;14(5):559-62. Review.

PMID:
11984156
35.

Familial primary biliary cirrhosis and autoimmune cholangitis.

Agarwal K, Jones DE, Watt FE, Burt AD, Floreani A, Bassendine MF.

Dig Liver Dis. 2002 Jan;34(1):50-2.

PMID:
11930900
36.

Investigation of a mechanism for accelerated breakdown of immune tolerance to the primary biliary cirrhosis-associated autoantigen, pyruvate dehydrogenase complex.

Jones DE, Palmer JM, Bennett K, Robe AJ, Yeaman SJ, Robertson H, Bassendine MF, Burt AD, Kirby JA.

Lab Invest. 2002 Feb;82(2):211-9.

PMID:
11850534
37.

Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study.

Caronia S, Bassendine MF, Barry R, Mills P, Naoumov NV, Fox R, Lowes J, Hollanders D, Murray-Lyon L, Irving WL, Goldin RD, Foster GR; UK Amantadine Study Group.

J Hepatol. 2001 Oct;35(4):512-6.

PMID:
11682036
38.

Managing chronic hepatitis C acquired through intravenous drug use.

Jowett SL, Agarwal K, Smith BC, Craig W, Hewett M, Bassendine DR, Gilvarry E, Burt AD, Bassendine MF.

QJM. 2001 Mar;94(3):153-8.

PMID:
11259690
39.

Secretory autoantibodies in primary biliary cirrhosis (PBC).

Palmer JM, Doshi M, Kirby JA, Yeaman SJ, Bassendine MF, Jones DE.

Clin Exp Immunol. 2000 Dec;122(3):423-8.

40.

Experimental autoimmune cholangitis: a mouse model of immune-mediated cholangiopathy.

Jones DE, Palmer JM, Kirby JA, De Cruz DJ, McCaughan GW, Sedgwick JD, Yeaman SJ, Burt AD, Bassendine MF.

Liver. 2000 Oct;20(5):351-6.

PMID:
11092252
41.

Presentation and mortality of primary biliary cirrhosis in older patients.

Newton JL, Jones DE, Metcalf JV, Park JB, Burt AD, Bassendine MF, James OF.

Age Ageing. 2000 Jul;29(4):305-9.

PMID:
10985438
42.

CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis.

Agarwal K, Jones DE, Daly AK, James OF, Vaidya B, Pearce S, Bassendine MF.

J Hepatol. 2000 Apr;32(4):538-41.

PMID:
10782900
43.

The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects.

Welfare MR, Bassendine MF, Daly AK.

Br J Clin Pharmacol. 2000 Mar;49(3):240-3.

44.

Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease.

Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP.

Gut. 2000 Apr;46(4):540-5.

45.

Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians.

Welfare MR, Aitkin M, Bassendine MF, Daly AK.

Pharmacogenetics. 1999 Jun;9(3):367-75. Erratum in: Pharmacogenetics 1999 Dec;9(6):782.

PMID:
10471069
46.

Comparison of cytotoxic T-lymphocyte responses to hepatitis C virus core protein in uninfected and infected individuals.

Jackson M, Smith B, Bevitt DJ, Steward M, Toms GL, Bassendine MF, Diamond AG.

J Med Virol. 1999 Jul;58(3):239-46.

PMID:
10447419
47.

Genetic susceptibility to primary biliary cirrhosis.

Agarwal K, Jones DE, Bassendine MF.

Eur J Gastroenterol Hepatol. 1999 Jun;11(6):603-6. Review.

PMID:
10418930
48.

Breakdown of tolerance to pyruvate dehydrogenase complex in experimental autoimmune cholangitis: a mouse model of primary biliary cirrhosis.

Jones DE, Palmer JM, Yeaman SJ, Kirby JA, Bassendine MF.

Hepatology. 1999 Jul;30(1):65-70.

PMID:
10385640
49.

T cell responses to the putative dominant autoepitope in primary biliary cirrhosis (PBC).

Palmer JM, Diamond AG, Yeaman SJ, Bassendine MF, Jones DE.

Clin Exp Immunol. 1999 Apr;116(1):133-9.

50.

Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer.

Welfare M, Monesola Adeokun A, Bassendine MF, Daly AK.

Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 1):289-92.

Supplemental Content

Loading ...
Support Center